Brief: RenovoRx Q3 Net Income USD -1.421 Million
14/11/2023 13:30
Nov 14 (Reuters) - RenovoRx Q3 basic EPS USD -0.13. * Q3 operating expenses USD 2.983 million * Q3 operating income USD -2.983 million
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer